Malta - English - Medicines Authority

synthon bv microweg 22, 6545 cm nijmegen, netherlands - lenalidomide - hard capsule - lenalidomide 20 milligram(s) - immunosuppressants

Malta - English - Medicines Authority

synthon bv microweg 22, 6545 cm nijmegen, netherlands - lenalidomide - hard capsule - lenalidomide 25 milligram(s) - immunosuppressants

Malta - English - Medicines Authority

synthon bv microweg 22, 6545 cm nijmegen, netherlands - lenalidomide - hard capsule - lenalidomide 2.5 mg - immunosuppressants

Malta - English - Medicines Authority

synthon bv microweg 22, 6545 cm nijmegen, netherlands - lenalidomide - hard capsule - lenalidomide 5 mg - immunosuppressants

Malta - English - Medicines Authority

synthon bv microweg 22, 6545 cm nijmegen, netherlands - lenalidomide - hard capsule - lenalidomide 7.5 mg - immunosuppressants

Malta - English - Medicines Authority

synthon bv microweg 22, 6545 cm nijmegen, netherlands - lenalidomide - hard capsule - lenalidomide 10 mg - immunosuppressants

Malta - English - Medicines Authority

synthon bv microweg 22, 6545 cm nijmegen, netherlands - lenalidomide - hard capsule - lenalidomide 15 mg - immunosuppressants

Malta - English - Medicines Authority

synthon bv microweg 22, 6545 cm nijmegen, netherlands - lenalidomide - hard capsule - lenalidomide 20 mg - immunosuppressants

Malta - English - Medicines Authority

synthon bv microweg 22, 6545 cm nijmegen, netherlands - lenalidomide - hard capsule - lenalidomide 25 mg - immunosuppressants

Israel - English - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - lenalidomide - hard capsule - lenalidomide 10 mg - lenalidomide - multiple myeloma (mm)lenalidomide s.k. is indicated for the treatment of multiple myeloma. myelodysplastic syndromes lenalidomide s.k. is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. lenalidomide s.k. 7.5 mg is not indicated for treatment in mds. mantle cell lymphoma lenalidomide s.k. is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl). follicular lymphomalenalidomide s.k. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.